Diisopropylethylamine → 4-(((3S,4S)-1-(1-cyanocyclopropanecarbonyl)-4-ethylpyrrolidin-3-yl)amino)-6-(6-((2-methoxyacetamido)methyl)pyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide

HRID 877783

Reaktionsgleichung

Reaktionsgleichung von HRID 877783
[CH2:1]([C@H:3]1[CH2:7][NH:6][CH2:5][C@H:4]1[NH:8][C:9]1[C:10]2[N:11]([CH:18]=[C:19]([C:21]3[CH:22]=[N:23][C:24]([CH2:27][NH:28][C:29](=[O:33])[CH2:30][O:31][CH3:32])=[CH:25][CH:26]=3)[CH:20]=2)[N:12]=[CH:13][C:14]=1[C:15]([NH2:17])=[O:16])[CH3:2].[C:34]([C:36]1([C:39](O)=[O:40])[CH2:38][CH2:37]1)#[N:35].CN([P+](ON1N=NC2C1=CC=CC=2)(N(C)C)N(C)C)C.F[P-](F)(F)(F)(F)F.CCN(C(C)C)C(C)C>CN(C=O)C>[C:34]([C:36]1([C:39]([N:6]2[CH2:7][C@H:3]([CH2:1][CH3:2])[C@H:4]([NH:8][C:9]3[C:10]4[N:11]([CH:18]=[C:19]([C:21]5[CH:22]=[N:23][C:24]([CH2:27][NH:28][C:29](=[O:33])[CH2:30][O:31][CH3:32])=[CH:25][CH:26]=5)[CH:20]=4)[N:12]=[CH:13][C:14]=3[C:15]([NH2:17])=[O:16])[CH2:5]2)=[O:40])[CH2:38][CH2:37]1)#[N:35]

Komponenten

6

Edukt 4

HCID 81531DiisopropylethylamineHCID 151348Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphateHCID 27332591-Cyanocyclopropanecarboxylic acidHCID 682914624-(((3S,4S)-4-ethylpyrrolidin-3-yl)amino)-6-(6-((2-methoxyacetamido)methyl)pyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide

Produkt 1

HCID 665482874-(((3S,4S)-1-(1-cyanocyclopropanecarbonyl)-4-ethylpyrrolidin-3-yl)amino)-6-(6-((2-methoxyacetamido)methyl)pyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamideAusbeute 30 %

Reagenzien, Katalysatoren, Lösungsmittel 1

HCID 6228DimethylformamideLösungsmittel

Versuchsvorschrift

A mixture of 4-(((3S,4S)-4-ethylpyrrolidin-3-yl)amino)-6-(6-((2-methoxyacetamido)methyl)pyridin-3-yl)pyrrolo[1,2-b]pyridazine-3-carboxamide, 2hydroiodide (26 mg, 0.037 mmol), 1-cyanocyclopropanecarboxylic acid (12.25 mg, 0.110 mmol), BOP-reagent (48.8 mg, 0.110 mmol) and Hunig's Base (0.045 mL, 0.257 mmol) in DMF (1 mL) was stirred at rt overnight. The reaction mixture was purified via preparative LC/MS with the following conditions: Column: Waters XBridge C18, 19×200 mm, 5-μm particles; Guard Column: Waters XBridge C18, 19×10 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile:water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10-mM ammonium acetate; Gradient: 5-100% B over 15 minutes, then a 7-minute hold at 100% B; Flow: 25 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation to afford the title compound (6 mg, 0.011 mmol, 30% yield). 1H NMR (500 MHz, METHANOL-d4) δ 8.78 (dd, J=11.9, 2.0 Hz, 1H), 8.19-8.10 (m, 1H), 8.07-7.90 (m, 2H), 7.38 (dd, J=8.2, 3.7 Hz, 1H), 7.20-7.06 (m, 1H), 5.05 (t, J=4.2 Hz, 0.5H), 4.91 (t, J=4.5 Hz, 0.5H), 4.57 (s, 2H), 4.37-4.25 (m, 1.5H), 4.18 (d, J=11.4 Hz, 0.5H), 3.97 (s, 2H), 3.94-3.75 (m, 1.5H), 3.49-3.37 (m, 3.5H), 2.69-2.59 (m, 0.5H), 2.58-2.46 (m, 0.5H), 1.83-1.32 (m, 6H), 1.08-0.96 (m, 3H) fractional peaks are due to the presence of amide rotomers. MS (ES+) m/z: 545.1 (M+H); LC retention time: 1.15 min (analytical LCMS Method H).

Aufarbeitung

  1. customThe reaction mixture was purified via preparative LC/MS with the following conditions
  2. waitGradient: 5-100% B over 15 minutes
  3. customa 7-minute hold
  4. additionFractions containing the desired product
  5. customdried via centrifugal evaporation

Quellen und Nachweise

ORD-Eintrag
ord-88d03223f60b4421a1785e637cd60ee0
Quelldatensatz
uspto-grants-2015_03
Patentnummer
US08987268B2

Verknüpfte Notizen

Wird geladen…